Efficacy of Abatacept and Adalimumab in Patients with Early Rheumatoid Arthritis With Multiple Poor Prognostic Factors: Post Hoc Analysis of a Randomized Controlled Clinical Trial (AMPLE)

ConclusionThis analysis indicates a trend towards improved disease activity and physical function with abatacept versus adalimumab in patients with seropositive, erosive early RA.Trial RegistrationClinicalTrials.gov NCT00929864.FundingBristol-Myers Squibb.

http://link.springer.com/10.1007/s40744-019-00174-7

Source: Rheumatology and Therapy - October 21, 2019 Category: Rheumatology Source Type: research